• Nigericin: From Ion Gradients to Translation

  2026-08-28

  Nigericin is a potassium/hydrogen ion carrier that turns pH and membrane-gradient biology into a controllable research variable. This thought-leadership guide connects its ionophore mechanism with cancer-cell stress, GSDMD-linked cell death, and metabolism-informed antibiotic research while separating validated evidence from forward-looking hypotheses.

• Liposomal Ce6 PDT Drives Pyroptosis in Breast Cancer

  2026-08-28

  This study shows that liposomal chlorin e6 photodynamic therapy can eliminate breast cancer cells through mitochondrial oxidative damage, caspase-1 activation, and pyroptosis rather than relying only on conventional apoptosis. In mouse models, the treatment also promoted immunogenic cell death and antitumor immunity, while combining PDT with the immune checkpoint inhibitor BMS202 improved tumor control and immune-cell infiltration.

• Pyruvate Carboxylase, Ferroptosis, and NSCLC Progression

  2026-08-27

  A 2026 Cancer Letters study identifies pyruvate carboxylase (PC) as a metabolic regulator of ferroptosis resistance in non-small cell lung cancer. The work connects ATP-dependent PC activity with AMPK suppression, AKT–mTOR signaling, fatty acid synthesis, and the PPARα–ACSL4 axis, while implicating DTX1 and USP51 as upstream regulators and supporting combined USP51 inhibition and anti-PD-1 therapy as a preclinical strategy.

• Ranolazine Workflows for Cardiac Ischemia Research

  2026-08-27

  Ranolazine enables a practical bridge between late sodium current inhibition, calcium handling, and metabolic stress assays. This workflow guide covers stock preparation, ischemia modeling, glucose oxidation enhancement, liver-cell extensions, and troubleshooting without treating exploratory findings as clinical evidence.

• KR-12 Structure–Function Mapping in Antimicrobial Action

  2026-08-26

  The reference study used targeted mutagenesis to show that KR-12 basic residues have position-dependent roles in membrane binding, lipid clustering, helicity, and bacterial killing. Its findings caution against treating cationic charge as a standalone design rule and provide a framework for interpreting KR-12 analogs in antimicrobial research.

• Rucaparib DNA-Repair Workflows for Cancer Research

  2026-08-26

  Build practical PARP-inhibition assays around Rucaparib (AG-014699), from DNA-damage imaging to clonogenic radiosensitization. The workflow also translates emerging SmD2–splicing findings into testable experiments in hepatocellular carcinoma without confusing validated evidence with hypothesis-driven extensions.

• KR-12 Design Principles and Translational Potential

  2026-08-25

  The 2024 review presents KR-12 as a compact human cathelicidin fragment and a modular platform for antimicrobial, anti-biofilm, endotoxin-neutralizing, and immune-regulatory design. Its central practical insight is that sequence editing, conjugation, macrocyclization, nan formulation, and surface immobilization can tune activity and stability, although heterogeneous evidence and context-dependent performance remain important translational limitations.

• Arterial and Venous Thrombus-Targeting Nanosystems

  2026-08-25

  This study systematically compares molecular recognition, enzyme-driven chemotaxis, and combined targeting in arterial and venous thrombus models. Its central finding is that low-flow venous thrombi can be addressed effectively with chemotactic motion, whereas high-flow arterial thrombi require combined targeting to improve nanosystem retention and thrombolytic efficacy.

• Adefovir C6629: Reliable HBV Assay Design

  2026-08-24

  Learn how Adefovir (SKU C6629) can support controlled HBV antiviral, cell viability, proliferation, and OAT1 transporter workflows. This scenario-based guide covers mechanism, concentration selection, aqueous stock preparation, data interpretation, and practical product-selection criteria.

• ER-Targeted EISA Peptides and Cancer Cell Fate

  2026-08-24

  The reference study develops an alkaline-phosphatase-triggered peptide that self-assembles at the endoplasmic reticulum through incorporation of a p-toluenesulfonamide targeting group. This organelle-focused enzyme-instructed self-assembly selectively increases ER stress and cancer-cell death, while lowering the concentration required for activity relative to a nontargeted intracellular design.

• KR-12–Cu(II) Binding: Mechanistic Insights

  2026-08-23

  The 2024 Dalton Transactions study combines potentiometric titration, isothermal titration calorimetry, and GFN2-xTB/ALPB calculations to define how the LL-37-derived peptide KR-12 interacts with Cu(II). Its central contribution is a molecular-level explanation showing that peptide backbone oxygen atoms dominate favorable coordination, while Asp26 and Arg29 are especially important for the observed binding behavior.

• 10058-F4: c-Myc-Max Dimerization Inhibitor

  2026-08-22

  10058-F4 is a c-Myc-Max dimerization inhibitor that prevents c-Myc/Max complex formation and suppresses c-Myc-dependent transcription. Product data support its use in acute myeloid leukemia research, apoptosis assays, and prostate cancer xenograft model workflows, with defined solvent and storage requirements.

• ATG4B Nuclear Translocation and AML DNA Repair

  2026-08-22

  The 2025 Advanced Science study identifies energy deficiency-induced nuclear translocation of ATG4B as a mechanistic link between metabolic stress, impaired PRMT1–MRE11 DNA repair, and acute myeloid leukemia progression. Its cellular, mouse, and patient-derived models suggest that inhibiting ATG4B can reinforce DNA damage responses, reduce genomic evolution, and extend survival in AML models.

• MEK1/2, c-Myc:MAX, and TERT in Stem Cells

  2026-08-21

  The reference study identifies a signaling–chromatin mechanism in which MEK1/2 and c-Myc:MAX cooperate to maintain TERT transcription in human pluripotent stem cells. Its findings connect MAPK activity and protection from PRC2-mediated repression, providing a mechanistic framework for understanding telomerase regulation in normal stem-cell models.

• Chlorin e6: From ROS to Translational PDT

  2026-08-20

  A translational roadmap for using Chlorin e6 to connect light delivery, mitochondrial ROS, pyroptosis, immune activation, assay design, and clinical strategy in photodynamic therapy research.

8086 records 1/540 page Next 12345 下5页 Last page